Anthracyclines and taxanes have remarkable anticancer efficacy, but have poor selectivity and high toxicity. Targeted delivery of chemotherapeutics has emerged as a strategy to achieve higher drug levels at the tumor site, to spare noncancerous tissue and potentially to use lower systemic drug doses, thus preventing side effects. In this study, we targeted the HER2 receptor using the monoclonal antibody (mAb) Herceptin (Trastuzumab) chemically conjugated to Doxorubicin or Taxol. In vitro, drug-Herceptin conjugates exhibited cytotoxicity comparable to equimolar concentrations of free drugs, with the benefit that the cytotoxicity of the conjugates was selective for cells expressing the HER2 target. In vivo, treatment of tumor-bearing mice with Taxol-Herceptin conjugates had a reduction of primary tumors comparable to equivalent doses of free drugs. However, Taxol-Herceptin conjugates significantly reduced metastasis compared with equivalent doses of free drugs. Thus, the data support the concept that conjugates might target metastasis better than primary tumors. This would offer a potential therapeutic approach for management of metastatic breast cancer.
INTRODUCTION
Anthracyclines and taxanes are established as first-line chemotherapeutics for the treatment of breast, ovarian, prostate and lung cancers. 1, 2 Doxorubicin is an anthracycline that intercalates into DNA, inhibits topoisomerase II and stabilizes DNA strand breaks, which ultimately triggers cell death. 3 Paclitaxel (Taxol) stabilizes the microtubule polymer and prevents its disassembly, leading to a cell cycle arrest at the G2/M phase and subsequent apoptosis. 4, 5 However, Doxorubicin and Taxol are not tumor selective and cause side effects, such as myelosuppression, cardiotoxycity and neurotoxicity. [6] [7] [8] [9] Lack of selectivity and high toxicity are the most important factors for discontinuation of cancer chemotherapy.
On the other hand, monoclonal antibodies (mAbs) directed against tumor antigens ('tumor markers') have high specificity. [10] [11] [12] However, antibody-based cancer therapy is generally not potent, and treatments are often limited in scope. In addition, they require high mAb doses or frequency, they are often used as adjuvant to chemotherapy and are very expensive. For example, Herceptin is a recombinant humanized mAb directed against the extracellular domain of the human epidermal growth factor receptor 2 protein (HER2, ErbB2, Neu). 13, 14 The HER2 gene is amplified and/or overexpressed in 20-25% of invasive breast cancers and is associated with tumor resistance to chemotherapy and poor patient survival. [15] [16] [17] [18] HER2 has been validated for targeted therapy. 16, [19] [20] [21] Current treatment for HER2-positive tumors uses mAb Herceptin, either concurrent with or sequential with systemic chemotherapy with anthracyclines or taxanes; [22] [23] [24] for review see Ross et al. 25 The combination improves survival in some patients. [26] [27] [28] Nevertheless, even with adjuvant therapy, the majority of patients who achieve an initial response to Herceptin-based regimens develop resistance within 1 year (for review, see de Azambuja et al. 29 ). Conjugates of chemotherapeutics and mAbs harness the specificity of a mAb to deliver a potent cytotoxic agent to the target tumor. Such strategy has been shown to significantly enhance therapy while reducing systemic toxicity 20, 21, 30 (reviewed in Alley et al. 31 and Guillemard et al. 32 ). A Herceptin conjugate, called Herceptin-DM1, has been reported to be effective in vivo versus cancer cell lines overexpressing HER2 receptor. 33 However, that study did not address two critical issues. First, the impact upon metastatic nodules was not studied. Second, a systematic comparison of dose and frequency using the same route of administration was not done. Therefore, it remains unclear whether Herceptin conjugates have an impact on metastasis, and whether the therapeutic window is improved by drug conjugation.
Here, we report the in vitro and in vivo potency of targeted cytotoxic conjugates containing Doxorubicin or Taxol as effector molecules and the mAb Herceptin to target HER2-expressing tumors. In vitro, cell killing by the drug-Herceptin conjugates is equivalent to the combination of free drug þ free Herceptin, but the conjugates have the added advantage of HER2 target specificity. Therapeutic studies using a highly metastatic HER2 þ breast cancer tumor xenografted in mice showed that TaxolHerceptin conjugates significantly reduced the number of metastatic lung nodules, and mice treated with conjugates feared better than approximately 30-fold higher doses of free Taxol. Taxol-Herceptin conjugates were also significantly more effective than equivalent doses of free Taxol þ free Herceptin, when tested at low doses and low frequency.
Our study further supports the development of antibody-drug conjugate strategies in cancer therapy, and in particular for the treatment of metastasis. Antibodies that have demonstrated poor efficacy or poor tolerability in vivo may benefit from this approach.
RESULTS
In vitro cytotoxicity of free drugs versus Herceptin-drug conjugates The cytotoxicity of a range of concentrations of free Doxorubicin (0.002-200 mM) or free Taxol (0.005-50 mM), or the Herceptin antibody (0.02-2 mM), was studied. The indicated cells were cultured for 48 h with drugs or controls, after which MTT assays gauged cell viability.
The cytotoxic effect of Doxorubicin and Taxol were comparable in NIH-HER2 and NIH-IGF1R cells ( Figure 1a and Table 1 ). These data indicate that free Doxorubicin and free Taxol are not HER2 selective, as expected for nontargeted chemotherapeutics. Herceptin had no cytotoxicity on any cell type in vitro, whether or not the cells express the HER2 target ( Figure 1b and Table 1 ). Moreover, free Herceptin did not potentiate cytotoxicity of free drugs. A 'grid' of concentrations was tested for combinations of free Herceptin (0.005-0.5 mM) þ free drug (0.001-0.5 mM) and they did not increase the cytotoxicity of free chemotherapeutics. As an example, we show that free Herceptin (0.05 mM) did not increase the cytotoxicity of free Doxorubicin (0.1 mM) against NIH-HER2 cells (Figure 1b) .
Together, these results indicate that mAb Herceptin is innocuous in vitro. This was expected and is consistent with the literature showing that Herceptin does not kill cells in vitro in the absence of other effectors such as lymphoid cells or complement.
In contrast, the Doxorubicin-Herceptin conjugate was efficacious and comparable to or better than free Doxorubicin at equimolar concentrations (compare Figures 1a and c) . Moreover, the Doxorubicin-Herceptin conjugate is selective toward cells expressing the HER2 target, and spares cells that do not express HER2. A range of doses was tested for each compound against several cell lines, to determine a lethal dose, LD 50 , experimentally. For all cells tested, the LD 50 of the conjugates was better than or equal to that of free drugs. The conjugates have the added benefit of target specificity, because in the control NIH-IGF1R cells even the highest doses of drug-Herceptin conjugates did not reach an LD 50 (Table 1) .
Characterization of Herceptin-drug conjugates Previously, we have shown that the conjugation strategy we use here yields ligands that bind the intended receptor with properties identical to the unconjugated ligand, which are able to internalize the complex in a receptor-dependent manner and which deliver the chemotherapeutic cargo inside the targeted cells. 20, 30, 32, 34 Moreover, we showed that conjugation of irrelevant antibodies does not result in drug uptake or cytotoxicity, 20, 32 indicating that the conjugate must bind to a cell surface target to be effective.
We have characterized the Herceptin conjugates used in the present report (only some data are shown as examples). For example, target selectivity is shown in Figure 1 and Table 1 . Supplementary Figure 1 shows that the binding properties of the conjugates are identical to the unconjugated Herceptin. Moreover, Figure 1d shows that adding a 10-fold molar excess of Herceptin blocked the cytotoxicity of the drug-Herceptin conjugate. These studies are feasible because free Herceptin does not kill cells in vitro. Cell killing by the Doxorubicin-Herceptin conjugate (0.2 mM, Doxorubicin-equivalent) was partially abolished (approximately 30% hindrance, Po0.05) by blocking the target with 2 mM Herceptin ( Figure 1d ). These 'cold competition' results suggest that the killing by the Doxorubicin-Herceptin conjugate requires binding to the HER2 receptor.
In vivo cytotoxicity of free drugs versus Herceptin-drug conjugates For further studies in vivo, we selected the Taxol-Herceptin conjugate, because this chemotherapeutic does not increase the risk of host cardiotoxicity associated with Doxorubicin treatment. We tested the therapeutic potential of the Taxol-Herceptin conjugate against the human breast adenocarcinoma MDA-231 cells engineered to express ErbB2. The cells were implanted into the mammary fat pad of female SCID mice. This cell model has been well characterized in terms of Her2 signaling and their unique property of highly metastasizing to lungs, thereby providing a relevant model to test the impact of experimental therapeutics on Her2-driven metastasis. 35 See the experimental flowchart described in Figure 2a .
In initial studies, designed to evaluate effectiveness, mice were treated intraperitoneally with a relatively high frequency (every 3 days, total of 10 injections) and at a relatively high dose. In each injection, groups of mice received either a Taxol-Herceptin conjugate (100 mg Herceptin with 2.4 mg Taxol equivalent) or a combination of 100 mg of free Herceptin þ 2.4 mg of free Taxol. As controls, phosphate-buffered saline (PBS) or the experimentally determined tolerated dose of 70 mg of free Taxol was used. Note that this dose of free Taxol is approximately 30-fold higher than the Taxol carried in the conjugates.
The groups of mice injected with the combination of free Taxol þ free Herceptin or with Taxol-Herceptin conjugate showed a significant and comparable reduction in tumor load from day 25 onward (Pp0.01 versus PBS control). In contrast, the primary tumor volume increased over time in the PBS and in the Taxoltreated groups (Figure 2b ).
Analyses of lung metastasis at the experimental end point day 47 showed that free Taxol þ free Herceptin or Taxol-Herceptin conjugate groups had a significant reduction in lung metastasis, 22% ± 1 and 21%±3 metastasis per lung, respectively (Pp0.001 versus PBStreated group, which is standardized to 100%) ( Figure 2d ). A 30-fold higher dose of free Taxol also partially decreased the number of nodules (65% ± 13 nodules per lung; Pp0.05 compared with the PBS-treated group); however, the free Taxol þ free Herceptin or Taxol-Herceptin conjugate groups performed significantly better than high-dose free Taxol (Pp0.05) (Figure 2d ).
These data indicate that at these doses and frequency of treatment the free drugs in combination are equally effective to the conjugated drugs and clearly reduce the number of metastatic lung nodules. In contrast, free Taxol is only advantageous for diminishing metastasis, and only when administered at relatively high doses.
Enhanced therapeutic window of Herceptin-drug conjugates The drug delivery schedule was altered to reduce dose and frequency. Mice were treated intraperitoneally with a relatively low frequency (once a week, for a total of five injections) at a relatively low dose of compounds. In each injection, groups of mice received either the Taxol-Herceptin conjugate (50 mg Herceptin equivalent and 1.2 mg Taxol equivalent) or a combination of 50 mg of free Herceptin þ 1.2 mg of free Taxol. PBS was the control. Given that high dose and frequency of free Taxol alone had no effect on primary tumors (Figure 2b ), this control was omitted.
A combination of free Taxol þ free Herceptin significantly reduced the primary tumor volume from day 35 onward (Pp0.01 versus PBS control). Treatment with the TaxolHerceptin conjugate affords better tumor therapy from day 35 onward (Pp0.001 versus PBS control; and Pp0.01 versus the combination of free Taxol þ free Herceptin) (Figure 2c) .
Better therapy by the conjugate was also evident in lung metastasis. The group treated with conjugate had a significantly lower index of metastasis (Pp0.01 versus PBS control; and Pp0.05 versus the combination of free Taxol þ free Herceptin). In contrast, the free Taxol þ free Herceptin combination did not cause a significant reduction in the number of nodules compared with the control PBS group (Figure 2e ). For representative pictures see Figure 3 .
These results indicate that at lower doses/frequency the efficacy of the Taxol-Herceptin conjugate is significantly better than the combination of the free drugs, for control of both the primary tumor and the metastasis.
None of the treatments shown (high dose/frequency and low dose/frequency) caused detectable toxicity to any of the groups of mice. The blood urea nitrogen and Amylase levels, body weights, cage activity or the condition of the animal fur all appeared to be normal (Table 2 , and data not shown).
DISCUSSION
We have studied the effect of the HER2-directed antibody Herceptin conjugated to the chemotherapeutics Doxorubicin or Taxol. Our data show that Herceptin conjugates have an enhanced cytotoxicity, improved efficacy and selectivity in vitro, and improved efficacy in vivo, compared with free drugs, especially when administered at low doses and low frequency. Therefore, this could be a promising strategy to maintain high and selective tumor cytotoxicity while at the same time reducing drug use, reducing undesirable side effects and reducing costs.
In vitro characterization of conjugates Free Doxorubicin and free Taxol are nonselective and kill all cells that were tested, in a dose-dependent manner, regardless of whether they express HER2. Exposure of cells to free Herceptin Figure 1 ). Lack of Herceptin cytotoxicity in vitro has been observed in various breast cancer cell lines, 33 and it is most likely due to the absence of antibody-dependent cellular cytotoxicity in cell cultures, which require addition of effector cells 36 or addition of complement. 37 Hence, in our in vitro culture model Herceptin acts merely as a carrier, and the cytotoxicity is only attributable to the drug being carried by Herceptin. Indeed, in our studies, free Herceptin combined with free drug did not potentiate the cytotoxicity of the free drug. In contrast, the cytotoxicity of drug-Herceptin conjugates was better than equimolar doses of free drug, and it was selective for HER2-expressing cells. Better killing in vitro by the conjugate may be explained by a more efficient transport or longer retention of the drug, which is released from the conjugate inside the targeted cell, as previously shown for the conjugation chemistry depicted here. 32 The selectivity of the conjugate is based on the cytotoxic effect being dependent on the expression of the target receptor, 19, 30, 32, 38 and this is further demonstrated by 'cold competition' studies in vitro, where unconjugated Herceptin blocked the cytotoxicity of conjugated Herceptin. This is consistent with other published 'cold competition' studies. 
Improving the efficacy of targeted therapy A Galan Garcia et al
Target specificity has been demonstrated for another Herceptin conjugate, called Herceptin-DM1, whereas HER2 receptor-negative cells escaped from Herceptin-DM1 cytotoxic action. 33 In vivo characterization of conjugates Herceptin in combination with chemotherapy is primarily used as therapy for metastatic breast cancer. Our data indicate that the number of metastatic lung nodules were significantly reduced in mice treated with high dose and high frequency of Herceptin (5 mg/kg) þ free Taxol (0.12 mg/kg), or with Taxol-Herceptin conjugate (delivering 5 mg/kg Herceptin and 0.12 mg/kg Taxol). Both these treatments were equally effective when they were administered twice a week for 5 weeks. In contrast, free Taxol alone was ineffective at reducing primary tumor and lung metastasis even when administered at 30-fold higher doses of 3.6 mg/kg. Thus, in our experimental model the therapeutic effect in vivo is mediated primarily by Herceptin, as suggested by other works. 39, 40 Importantly, even a reduced treatment frequency and dose of the Taxol-Herceptin conjugate remained effective at diminishing metastatic lung nodules, with little impact on the primary tumor. This is significant because equivalent lower dose/frequency of free Taxol þ free Herceptin treatment did not resolve either the primary tumor or the lung metastasis. To our knowledge, this is the first report of a treatment that has a selective impact upon metastasis without affecting the primary tumor. This is remarkable because the 'primary tumor' may be removed surgically, but metastasis continues to be the main cause of mortality. In addition, it is noteworthy that the therapeutic paradigms follow an optimized regimen for Herceptin. It is likely that the Herceptin conjugate could be further optimized in preclinical trials.
Comparisons with other conjugates At present, Herceptin-DM1 is the only Herceptin antibody-drug conjugate in late-stage clinical trials. 31, 41 It is therefore important to compare it vis a vis our results because in experimental models of breast cancer Herceptin-DM1 conjugate had a significant effect in reducing primary tumor growth. There are three major experimental design differences between the study by Lewis Phillips et al. 33 and our study. First, Herceptin-DM1 treatment resulted in almost complete disappearance of the primary tumor, whereas our conjugated Herceptin-Taxol reduced tumor burden but did not eliminate primary tumors completely in any of the mice. This could be because of different cell lines being used in each study (MDA-231-ErbB2 cells in our study versus KPL-4 cells in the Herceptin-DM1 study). Second, in our study the frequency and route of administration of all drugs tested for each experimental paradigm were equivalent, whereas Herceptin-DM1 treatment was administered intravenously in one single bolus at day 0 and was compared with free Herceptin administered intraperitoneally multiple times. Third, the doses of free Herceptin and Herceptin-DM1 were higher (15 mg/kg) than the dose of free Herceptin and Herceptin-Taxol conjugate that we used in the 'low frequency model' (2.5 mg/kg).
Conclusions
As Taxol-and Herceptin-based therapies entail high systemic toxicity and high economic cost, improved therapy by selective cytotoxic agents used at lower effective doses circumvents the main drawbacks of conventional anticancer drugs. The combination of anthracyclines or taxanes with Herceptin is the current therapy used to fight HER2-positive breast cancer. It is therefore important to develop conjugation strategies to deliver these conventional drugs.
We report the effect of Herceptin-Doxorubicin and HerceptinTaxol conjugates in vitro and Herceptin-Taxol in vivo. Their improved selectivity, efficacy and specificity, with no detectable systemic toxicity, reassert the valuable potential of antibody-drug conjugation strategies in cancer treatment, in particular for the treatment of metastasis. Antibodies that have demonstrated poor efficacy or poor tolerability in vivo may benefit from this approach.
MATERIALS AND METHODS

Cell lines and antibodies
NIH-HER2 and NIH-IGF1R cells are NIH-3T3 mouse fibroblasts stably transfected with human HER2 cDNA and human IGF-1R cDNA, respectively. 30, 32, 42 The human breast cancer cell line MDA-231 was obtained from the American Type Culture Collection. The ErbB-2 receptor was overexpressed using a bicistronic retrovector, which coexpresses the ErbB-2 receptor with the enhanced green fluorescent protein (EGFP) as described previously. 43 MDA-231-ErbB2 cells are highly metastatic to lung. 44 All cells were cultured at 37 1C and 5% CO 2 and maintained in RPMI 1640 medium supplemented with 5% (NIH-HER2 and NIH-IGF1R) or 10% fetal bovine serum (MDA-231), with penicillin and streptomycin antibiotics 
Synthesis of Taxol-Herceptin conjugate
Taxol-Herceptin conjugate was developed and characterized as previously published by our laboratory for many other proteins. 32, 34 The carboxyl function of Taxol-2 0 -glutarate (4.06 mg, 4.2 mmol, FW ¼ 968) was activated by the addition of N-hydroxysuccinimide (0.53 mg, 4.6 mmol, FW ¼ 115.1) and EEDQ (N-ethoxy-carbonyl-2-ethoxy-1,2-dihydroquinoline) (1.04 mg, 4.2 mmol, FW ¼ 247.3) in dry N,N-dimethylformamide (500 ml) and stirring at 0 1C for 1 h. The activated ester was used for the conjugation reaction and was added at room temperature to the antibody in PBS (Herceptin, 33 mM). The reaction proceeded for 16 h at 41 C. As a result, a Taxolantibody conjugate was formed via peptide bond with the amino groups in the protein. 30 The solution was then dialyzed for 2 h against PBS and overnight against PBS using dialysis membranes of cutoff 12-14 kDa.
For quantification of the conjugate, a specific known amount was hydrolyzed in 0.1 M acetate buffer. The Taxol was extracted with CHCl 3 , the solvent was evaporated and the Taxol was quantified by HPLC (Varian Analytical Instruments, Walnut Creek, CA, USA). Known concentrations of Taxol were used as a standard. The concentration of the protein was determined by spectroscopy (Nanodrop 1000). After quantification the average ratio Taxol: mAb was found to range from 5:1 to 7:1 for several independent conjugations. When reporting a dose for a conjugate, we use 'Taxol-equivalent units', which is the molarity of the mAb multiplied by the stoichiometry of the drug conjugated.
Synthesis of the Doxorubicin-Herceptin conjugate
Synthesis of the Doxorubicin-Herceptin conjugate was developed and characterized as previously published by our laboratory for many other proteins. 32, 34 We derivatized 2 mg/ml Herceptin with 10 mM sodium periodate in 0.1 M acetate buffer, pH 5.5, for 30 min, 45 leading to the formation of reactive aldehyde groups. We removed byproducts by size exclusion and exchanged the buffer to 1 M carbonate/bicarbonate buffer, pH 9.0. We added Doxorubicin (40 mg), dissolved in 40 ml carbonate buffer, and the reaction proceeded for 16 h at 4 1C. A Doxorubicin-antibody conjugate formed via Schiff's bases between reactive aldehydes of the antibody and the amino group of the drug. We then reduced the conjugate (50 mM pyridine borane, 24 h at 4 1C) to stabilize the Schiff's bases, leading to the formation of a C-N linkage between the antibody and the drug. 46 We finally dialyzed the conjugate against PBS. The stoichiometry of doxorubicin:mAb was quantified using spectroscopy at 495 nm, using known concentrations of Doxorubicin as standard control. We measured an average 1:2 molar ratio of antibody to Doxorubicin, meaning that on average two Doxorubicin molecules couple to one antibody molecule. When reporting a dose for a conjugate we use 'Doxorubicin-equivalent units', which is the molarity of the mAb multiplied by the stoichiometry of the drug conjugated.
Characterization of the target binding by Herceptin conjugates
These tests were conducted by FACScan (Becton Dickinson, San Jose, CA, USA) cell surface quantitative binding assays, as we previously published. 30, 32 The data demonstrated that the unconjugated Herceptin and the conjugated Herceptin have an equivalent capacity to saturate HER2-binding sites on the cell surface, with identical profiles at equal doses (see Supplementary Figure 1 ).
Cytotoxicity assays
Cell viability was determined by MTT assays measuring the absorbance of formazan formation. The breast cancer tumor cells MDA-231-ErbB2 and SKBR-3, and the engineered NIH-3T3 fibroblasts NIH-HER2 and NIH-IGF1R cells (transfected stably with HER2 or IGF-1R, respectively), were plated in 96-well plates at approximately 30% confluency. The indicated drugs (free Doxorubicin, free Taxol, free Herceptin, free Doxorubicin plus free Herceptin, free Taxol plus free Herceptin, Doxorubicin-Herceptin conjugate and TaxolHerceptin conjugate) were added 2 h after plating. The survival of the cells was measured 48 h after treatment. Untreated cells were set as 100%. In control experiments, the cytotoxicity of the conjugate was competed by adding a 10-fold molar excess of unconjugated Herceptin antibody.
In vivo xenograft tumor studies MDA-231-ErbB2 cells are breast cancer cells that are highly metastatic to lung, 44 and because of this feature they were chosen for our study. In vivo experiments were approved by the McGill University Animal Care Committee and were conducted in accordance with institutional and Canadian federal guidelines. Female SCID mice (8 weeks old, approximately 22 g, from Charles River Laboratory, St Zotique, QC, Canada) were used to test the effect of free drugs or conjugates in tumor progression and lung metastasis. Subconfluent MDA-231-ErbB2 cells were suspended in PBS and injected subcutaneously into the mammary fat pad (10 6 cells per mouse in 0.1 ml). Tumor growth was monitored daily. Tumor volume was measured starting at day 0. Two weeks after implantation, once the tumors were palpable, mice were blindly randomized to various experimental groups and treatment was initiated. The measurements of blood urea nitrogen levels and amylase levels were carried out as a service by the animal facility.
Treatment paradigms
All injections were intraperitoneal, in 100-ml volumes. All compounds were coded and treatment was blinded. All drug treatments were administered for 5 weeks.
In the first experimental paradigm, injections were administered every 3 days, for a total of 10 injections, at a relatively high dose of compounds. Four groups of mice (n ¼ 12 in each group) received vehicle PBS, 70 mg of free Taxol (approximately 3.2 mg/kg), 2.4 mg of free Taxol (approximately 110 mg/kg) þ 100 mg of free Herceptin or Taxol-Herceptin conjugate (100 mg Herceptin equivalent and 2.4 mg Taxol equivalent).
In the second experimental paradigm, injections were administered once a week, for a total of 5 injections, at a relatively low dose of compounds. Three groups of mice (n ¼ 15) received vehicle PBS, 50 mg of free Herceptin þ 1.2 mg of free Taxol or Taxol-Herceptin conjugate (50 mg Herceptin equivalent and 1.2 mg Taxol equivalent). These Taxol doses translate into approximately 55 mg/kg, because at the time of injection the mice weigh on average 22 g, and the weight standard deviations across groups are o5%.
Tumor monitoring
Tumor volumes were measured every day before treatment by external measurement using a caliper and the following equation: volume ¼ p/6 (length Â width 2 ). At study termination, animals were killed, primary tumors were isolated and weighed and lung surface metastatic nodules were counted using a stereoscope (Optimax; Leica Microsystems, Buffalo Grove, IL, USA). Two different researchers counted all lungs and the data were compared statistically. The number of metastatic nodules is presented as the percentage of colonies counted per lung by the two investigators. PBS control group was set as 100% of metastatic nodules.
Statistical analysis
Statistical analysis was conducted using Student's t-test. Data are expressed as means of three or more experiments ± s.e.m. LD 50 was calculated by plotting the average concentration of the drugs and curve fitting using the software Origin 8.0 (OriginLab Corporation, Northhampton, MA, USA).
